Asymptomatic Bacteriuria, Urinalysis Abnormality at the Initiation of SGLT2 Inhibitors and UTI Risk
NCT ID: NCT05520684
Last Updated: 2022-09-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
120 participants
OBSERVATIONAL
2022-02-15
2023-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
EFFECT SGLT2 INHIBITORS ON CONTRAST MEDIUM INDUCED ACUTE KIDNEY INJURY
NCT06288529
SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?
NCT04853615
The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease
NCT06528405
SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot
NCT06124924
Effect of Glycosuria on Urinary Protein in Patients With Chronic Kidney Disease Treated With SGLT2 Inhibitors
NCT07084038
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
positive for bacteriuria/ urinalysis abnormality
The patients who have any growth in urine culture or urinalysis abnormality at the initiation of SGLT2 inhibitor (dapagliflozin or empagliflozin)
urine culture and urinalysis
urine culture and urinalysis
negative for bacteriuria/ urinalysis abnormality
The patients who do not have growth in urine culture or do not have abnormality in urinalysis at the initiation of SGLT2 inhibitor (dapagliflozin or empagliflozin)
urine culture and urinalysis
urine culture and urinalysis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
urine culture and urinalysis
urine culture and urinalysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* \>18 years old
* Type 2 Diabetes Mellitus
* Initiated SGLT2 inhibitors
* Available informed consent
Exclusion Criteria
* Treated for urinary tract or genital tract infection in the last 3 months
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Trabzon Arakli Bayram Halil Public Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Erman Akkus
Internal Medicine Specialist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Erman Akkus, MD
Role: STUDY_CHAIR
Trabzon Arakli Bayram Halil Public Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Trabzon Araklı Bayram Halil Public Hospital
Trabzon, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Erman Akkus, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6111449
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.